vs
查尔斯河实验室（CRL）与吉利德科学（GILD）财务数据对比。点击上方公司名可切换其他公司
吉利德科学的季度营收约是查尔斯河实验室的8.0倍（$7.9B vs $994.2M），吉利德科学净利率更高（27.5% vs -27.8%，领先55.4%），吉利德科学同比增速更快（4.7% vs -0.8%），吉利德科学自由现金流更多（$3.1B vs $58.6M），过去两年吉利德科学的营收复合增速更高（8.9% vs -0.9%）
查尔斯河实验室国际是总部位于美国马萨诸塞州威尔明顿的医药及生物技术领域合同研究组织（CRO），成立于1947年，可为新药、疫苗及医疗器械的研发提供临床前和临床阶段的专业实验室服务。
吉利德科学是总部位于美国加利福尼亚州福斯特城的生物制药企业，专注于研发抗病毒药物，覆盖艾滋病、乙型肝炎、丙型肝炎、流感、新冠等治疗领域，核心产品包括来迪派韦索磷布韦、索磷布韦等，现为纳斯达克100指数及标普100指数成分股。
CRL vs GILD — 直观对比
营收规模更大
GILD
是对方的8.0倍
$994.2M
营收增速更快
GILD
高出5.5%
-0.8%
净利率更高
GILD
高出55.4%
-27.8%
自由现金流更多
GILD
多$3.1B
$58.6M
两年增速更快
GILD
近两年复合增速
-0.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $994.2M | $7.9B |
| 净利润 | $-276.6M | $2.2B |
| 毛利率 | — | 79.5% |
| 营业利润率 | -28.5% | 25.0% |
| 净利率 | -27.8% | 27.5% |
| 营收同比 | -0.8% | 4.7% |
| 净利润同比 | -28.9% | 22.4% |
| 每股收益（稀释后） | $-5.57 | $1.75 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CRLGILD
| Q4 25 | $994.2M | $7.9B | ||
| Q3 25 | $1.0B | $7.8B | ||
| Q2 25 | $1.0B | $7.1B | ||
| Q1 25 | $984.2M | $6.7B | ||
| Q4 24 | $1.0B | $7.6B | ||
| Q3 24 | $1.0B | $7.5B | ||
| Q2 24 | $1.0B | $7.0B | ||
| Q1 24 | $1.0B | $6.7B |
净利润CRLGILD
| Q4 25 | $-276.6M | $2.2B | ||
| Q3 25 | $54.4M | $3.1B | ||
| Q2 25 | $52.3M | $2.0B | ||
| Q1 25 | $25.5M | $1.3B | ||
| Q4 24 | $-214.5M | $1.8B | ||
| Q3 24 | $69.7M | $1.3B | ||
| Q2 24 | $94.1M | $1.6B | ||
| Q1 24 | $73.0M | $-4.2B |
毛利率CRLGILD
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 79.8% | ||
| Q2 25 | — | 78.8% | ||
| Q1 25 | — | 76.9% | ||
| Q4 24 | — | 79.1% | ||
| Q3 24 | 34.6% | 79.1% | ||
| Q2 24 | 34.5% | 77.8% | ||
| Q1 24 | 34.1% | 76.8% |
营业利润率CRLGILD
| Q4 25 | -28.5% | 25.0% | ||
| Q3 25 | 13.3% | 42.8% | ||
| Q2 25 | 9.7% | 34.9% | ||
| Q1 25 | 7.6% | 33.6% | ||
| Q4 24 | -16.7% | 32.4% | ||
| Q3 24 | 11.6% | 11.8% | ||
| Q2 24 | 14.8% | 38.0% | ||
| Q1 24 | 12.5% | -64.6% |
净利率CRLGILD
| Q4 25 | -27.8% | 27.5% | ||
| Q3 25 | 5.4% | 39.3% | ||
| Q2 25 | 5.1% | 27.7% | ||
| Q1 25 | 2.6% | 19.7% | ||
| Q4 24 | -21.4% | 23.6% | ||
| Q3 24 | 6.9% | 16.6% | ||
| Q2 24 | 9.2% | 23.2% | ||
| Q1 24 | 7.2% | -62.4% |
每股收益（稀释后）CRLGILD
| Q4 25 | $-5.57 | $1.75 | ||
| Q3 25 | $1.10 | $2.43 | ||
| Q2 25 | $1.06 | $1.56 | ||
| Q1 25 | $0.50 | $1.04 | ||
| Q4 24 | $-4.17 | $1.43 | ||
| Q3 24 | $1.33 | $1.00 | ||
| Q2 24 | $1.74 | $1.29 | ||
| Q1 24 | $1.30 | $-3.34 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $213.8M | $68.0M |
| 总债务越低越好 | $2.1B | $24.9B |
| 股东权益账面价值 | $3.2B | $22.7B |
| 总资产 | $7.1B | $59.0B |
| 负债/权益比越低杠杆越低 | 0.68× | 1.10× |
8季度趋势，按日历期对齐
现金及短期投资CRLGILD
| Q4 25 | $213.8M | $68.0M | ||
| Q3 25 | $207.1M | $19.0M | ||
| Q2 25 | $182.8M | $69.0M | ||
| Q1 25 | $229.4M | — | ||
| Q4 24 | $194.6M | — | ||
| Q3 24 | $210.2M | — | ||
| Q2 24 | $179.2M | — | ||
| Q1 24 | $327.0M | — |
总债务CRLGILD
| Q4 25 | $2.1B | $24.9B | ||
| Q3 25 | $2.2B | $24.9B | ||
| Q2 25 | $2.3B | $24.9B | ||
| Q1 25 | $2.5B | $25.0B | ||
| Q4 24 | $2.2B | $26.7B | ||
| Q3 24 | $2.3B | $23.2B | ||
| Q2 24 | $2.4B | $23.3B | ||
| Q1 24 | $2.7B | $25.2B |
股东权益CRLGILD
| Q4 25 | $3.2B | $22.7B | ||
| Q3 25 | $3.4B | $21.5B | ||
| Q2 25 | $3.4B | $19.7B | ||
| Q1 25 | $3.2B | $19.2B | ||
| Q4 24 | $3.5B | $19.3B | ||
| Q3 24 | $3.8B | $18.5B | ||
| Q2 24 | $3.7B | $18.3B | ||
| Q1 24 | $3.6B | $17.5B |
总资产CRLGILD
| Q4 25 | $7.1B | $59.0B | ||
| Q3 25 | $7.5B | $58.5B | ||
| Q2 25 | $7.6B | $55.7B | ||
| Q1 25 | $7.6B | $56.4B | ||
| Q4 24 | $7.5B | $59.0B | ||
| Q3 24 | $8.0B | $54.5B | ||
| Q2 24 | $7.9B | $53.6B | ||
| Q1 24 | $8.2B | $56.3B |
负债/权益比CRLGILD
| Q4 25 | 0.68× | 1.10× | ||
| Q3 25 | 0.64× | 1.16× | ||
| Q2 25 | 0.70× | 1.27× | ||
| Q1 25 | 0.79× | 1.30× | ||
| Q4 24 | 0.65× | 1.38× | ||
| Q3 24 | 0.62× | 1.26× | ||
| Q2 24 | 0.65× | 1.28× | ||
| Q1 24 | 0.73× | 1.44× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $147.5M | $3.3B |
| 自由现金流经营现金流 - 资本支出 | $58.6M | $3.1B |
| 自由现金流率自由现金流/营收 | 5.9% | 39.4% |
| 资本支出强度资本支出/营收 | 8.9% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.52× |
| 过去12个月自由现金流最近4个季度 | $518.5M | $9.5B |
8季度趋势，按日历期对齐
经营现金流CRLGILD
| Q4 25 | $147.5M | $3.3B | ||
| Q3 25 | $213.8M | $4.1B | ||
| Q2 25 | $204.6M | $827.0M | ||
| Q1 25 | $171.7M | $1.8B | ||
| Q4 24 | $159.4M | $3.0B | ||
| Q3 24 | $251.8M | $4.3B | ||
| Q2 24 | $193.5M | $1.3B | ||
| Q1 24 | $129.9M | $2.2B |
自由现金流CRLGILD
| Q4 25 | $58.6M | $3.1B | ||
| Q3 25 | $178.2M | $4.0B | ||
| Q2 25 | $169.3M | $720.0M | ||
| Q1 25 | $112.4M | $1.7B | ||
| Q4 24 | $83.7M | $2.8B | ||
| Q3 24 | $213.1M | $4.2B | ||
| Q2 24 | $154.0M | $1.2B | ||
| Q1 24 | $50.7M | $2.1B |
自由现金流率CRLGILD
| Q4 25 | 5.9% | 39.4% | ||
| Q3 25 | 17.7% | 51.0% | ||
| Q2 25 | 16.4% | 10.2% | ||
| Q1 25 | 11.4% | 24.8% | ||
| Q4 24 | 8.4% | 37.4% | ||
| Q3 24 | 21.1% | 55.2% | ||
| Q2 24 | 15.0% | 17.2% | ||
| Q1 24 | 5.0% | 31.6% |
资本支出强度CRLGILD
| Q4 25 | 8.9% | 2.6% | ||
| Q3 25 | 3.5% | 1.9% | ||
| Q2 25 | 3.4% | 1.5% | ||
| Q1 25 | 6.0% | 1.6% | ||
| Q4 24 | 7.5% | 1.9% | ||
| Q3 24 | 3.8% | 1.9% | ||
| Q2 24 | 3.8% | 1.9% | ||
| Q1 24 | 7.8% | 1.6% |
现金转化率CRLGILD
| Q4 25 | — | 1.52× | ||
| Q3 25 | 3.93× | 1.35× | ||
| Q2 25 | 3.91× | 0.42× | ||
| Q1 25 | 6.74× | 1.34× | ||
| Q4 24 | — | 1.67× | ||
| Q3 24 | 3.61× | 3.44× | ||
| Q2 24 | 2.06× | 0.82× | ||
| Q1 24 | 1.78× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CRL
| Discovery And Safety Assessment Segment | $591.6M | 60% |
| Manufacturing Support Segment | $196.4M | 20% |
| Transferred At Point In Time | $108.0M | 11% |
| Transferred Over Time | $98.3M | 10% |
GILD
| Other | $3.4B | 43% |
| HIV Products Biktarvy | $3.3B | 41% |
| HIV Products Odefsey | $239.0M | 3% |
| Liver Disease Products Other Liver Disease | $170.0M | 2% |
| HIV Products Other HIV | $155.0M | 2% |
| Other Products Yescarta | $150.0M | 2% |
| Liver Disease Products Vemlidy | $149.0M | 2% |
| Liver Disease Products Sofosbuvir Velpatasvir | $140.0M | 2% |
| HIV Products Symtuza Revenue Share | $98.0M | 1% |
| Veklury | $80.0M | 1% |
| Cell Therapy Products Tecartus | $32.0M | 0% |
| Royalty Contract And Other | $22.0M | 0% |
